ARN 6039

Drug Profile

ARN 6039

Alternative Names: ARN-6039

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arrien Pharmaceuticals
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists; Th17 cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis
  • Preclinical Psoriasis

Most Recent Events

  • 28 Jun 2017 ARN 6039 licensed to Undisclosed company worldwide
  • 28 Jun 2017 Arrien completes a phase I trial in Multiple sclerosis in USA (PO)
  • 03 Jun 2016 US FDA approves an IND application for ARN 6039 in Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top